We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oral Cancer Detection Increased with Saliva Test

By LabMedica International staff writers
Posted on 10 May 2012
A simple saliva test has been created which could identify the presence of biomarkers that are associated with oral cancer.

The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.

A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.

Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."

Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.

Related Links:

Michigan State University
University of California
Delta Dental



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
PURITAN MEDICAL